ISSN 2147-9720 | E-ISSN 2148-4279
Case Report
Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis
1 Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey  
2 Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey  
3 Department of Medical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey  
Eur J Rheumatol 2018; 5: 75-78
DOI: 10.5152/eurjrheum.2016.15081
Key Words: Still’s disease, pulmonary aspergillosis, tumor necrosis factor-alpha inhibitors, infliximab
Abstract

 

The use of anti-tumor necrosis factor alpha (anti-TNF-α) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-α agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression, and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-α agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still’s disease.

 

Cite this article as: Şeyhoğlu E, Erden A, Kılıç L, Karadağ Ö, Arıkan Akdağlı S, Akdoğan A, et al. Pulmonary aspergillosis after treatment with infliximab in Still’s disease and a literature review of Still’s disease and pulmonary aspergillosis. Eur J Rheumatol 2018; 5: 75-8.

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Medical Research and Education Association | Latest Update: 27.08.2018